Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alpha TeknovaTKNO -4.22%61 Debt-to-Equity is 0.44 as of Jun. 2026, which is 19% above its 10-year median of 0.37. GuruFocus rates TKNO with a GF Score™ of 61/100 and a GF Value™ of $4.45 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 810 Drug Manufacturers companies, Alpha Teknova ranks worse than 65.06% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Alpha Teknova's Debt-to-Equity or its related term are showing as below:
TKNO'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.37 Max: 0.72
Current: 0.44
During the past 7 years, the highest Debt-to-Equity Ratio of Alpha Teknova was 0.72. The lowest was 0.00. And the median was 0.37.
TKNO's Debt-to-Equity is ranked worse than 65.06% of 810
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs TKNO: 0.44
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Alpha Teknova Debt-to-Equity Related Terms
Alpha Teknova Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Alpha Teknova's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TKNO vs NIKA, BIOA, ELTP: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alpha Teknova's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpha Teknova Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alpha Teknova's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Alpha Teknova's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alpha Teknova (TKNO) has a Debt-to-Equity of 0.44 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Alpha Teknova and its competitors. This is 19% above median its historical median of 0.37. According to the industry distribution chart, Alpha Teknova ranks #527 out of 810 companies in the Drug Manufacturers industry, placing it in the top 65.1%.
Is Alpha Teknova's Debt-to-Equity too high?
Alpha Teknova's current Debt-to-Equity of 0.44 is 19% above median its 10-year median of 0.37. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Alpha Teknova's value of 0.44 is 57.1% above this industry median. Based on the distribution chart, Alpha Teknova ranks #527 out of 810 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Alpha Teknova has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alpha Teknova's Debt-to-Equity compare to NIKA and BIOA?
According to the Drug Manufacturers industry distribution chart, Alpha Teknova ranks #527 out of 810 companies for Debt-to-Equity. This places Alpha Teknova in the lower half of its industry. The industry median Debt-to-Equity is 0.28. Alpha Teknova's value of 0.44 is 57.1% above this benchmark. While the company's 10-year median is 0.37 vs. the industry median of 0.28, Alpha Teknova has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alpha Teknova's current Debt-to-Equity of 0.44 is 57.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Alpha Teknova and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alpha Teknova's current Debt-to-Equity is 0.44, which is 19% above median its own 10-year median of 0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Teknova stock overvalued right now?
Based on GuruFocus' analysis, Alpha Teknova (TKNO) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.45, compared to a current price of $6.92 — trading 55.5% above its estimated fair value. The current Debt-to-Equity is 0.44, which is 19% above median its 10-year median of 0.37 and 57.1% above the Drug Manufacturers industry median of 0.28. Alpha Teknova's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Alpha Teknova (TKNO), the current Debt-to-Equity is 0.44 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alpha Teknova (TKNO) Overvalued in 2026?
Based on GuruFocus' analysis, Alpha Teknova stock appears to be overvalued.
The current stock price of $6.92 is trading 55.5% above its estimated GF Value™ of $4.45.
GuruFocus considers Alpha Teknova to be Significantly Overvalued.
Key valuation signals for TKNO:
Debt-to-Equity: 0.44 (19% above median its 10-year median of 0.37)
GF Value™: $4.45 vs. price of $6.92 (55.5% above fair value)
Industry Position: 57.1% above the Drug Manufacturers median (#527 of 810)
No single metric tells the full story. See the TKNO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.
61GF Score
Get the complete analysis for TKNO
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TKNO has been successfully added to your 
